BIOS Fund II NT, LP — SEC Form 4 filings
SEC reporting owner CIK 1728851. 14 Form 4 filings on record with FilingPulse; latest filed 2025-06-30.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-01-19 to 2025-06-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 2 filings — 571,428 shares, $4,499,996 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 59 legs across 8 filings — 440,737 shares, $2,038,001 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 68.
- Largest priced transaction: purchase of 375,000 shares @ $8.00 ($3,000,000) in ACTUATE THERAPEUTICS, INC., filed 2024-08-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | Director, 10% owner | 4 | 3 legs · 571,428 sh · $4,499,996 | 6 legs · 49,998 sh · $424,983 | 52 |
| Lantern Pharma Inc. (LTRN) | 10% owner | 6 | — | 53 legs · 390,739 sh · $1,613,018 | 6 |
| IN8BIO, INC. | 10% owner | 2 | — | — | 7 |
| COGNITION THERAPEUTICS INC (CGTX) | Director, 10% owner | 2 | — | — | 3 |
Form 4 filings — BIOS Fund II NT, LP
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-06-30 | 4 | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Purchase (P): 71,428 @ $7 · Purchase (P): 71,428 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Memory SPV II, LP, BIOS Equity Partners III, LP, BIOS Fund III, LP, BIOS Fund III QP, LP, BIOS Fund III NT, LP, BP Directors, LP | Grant/award (A): 34,000 @ $0 | EDGAR |
| 2025-06-13 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 3 @ $3.40 · Sale (S): 171 @ $3.40 · Sale (S): 10,925 @ $3.38 · Sale (S): 5 @ $3.40 · Sale (S): 293 @ $3.40 · Sale (S): 18,678 @ $3.38 · +9 more | EDGAR |
| 2025-06-13 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 7,206 @ $3.09 · Sale (S): 12,319 @ $3.09 · Sale (S): 1,903 @ $3.09 · Sale (S): 14,218 @ $3.09 · Sale (S): 4,354 @ $3.09 | EDGAR |
| 2025-05-29 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 3,790 @ $3.05 · Sale (S): 2,702 @ $2.87 · Sale (S): 3,639 @ $3.03 · Sale (S): 6,479 @ $3.05 · Sale (S): 4,620 @ $2.87 · Sale (S): 6,221 @ $3.03 · +9 more | EDGAR |
| 2025-05-07 | 4 | IN8BIO, INC. jointly with Fletcher Aaron G.L., BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Incysus Co-Invest I, LP, Bios Clinical Opportunity Fund, LP, Bios Equity COF, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Purchase (P): 1,148,482 (derivative) · Other (J): 574,241 (derivative) · Other (J): 574,241 (derivative) | EDGAR |
| 2024-10-11 | 4 | IN8BIO, INC. (INAB) jointly with Fletcher Aaron G.L., BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Incysus Co-Invest I, LP, Bios Clinical Opportunity Fund, LP, Bios Equity COF, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Purchase (P): 709,040 (derivative) · Purchase (P): 709,040 (derivative) · Disposition to issuer (D): 574,241 (derivative) · Grant/award (A): 574,241 (derivative) | EDGAR |
| 2024-08-20 | 4/A | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Sale (S): 5,314 @ $8 · Sale (S): 17,361 @ $8 · Sale (S): 2,324 @ $8 | EDGAR |
| 2024-08-14 | 4 | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Conversion (C): 884,427 · Purchase (P): 375,000 @ $8 · Purchase (P): 125,000 @ $8 · Conversion (C): 525,797 · Conversion (C): 307,538 · Conversion (C): 141,457 · +50 more | EDGAR |
| 2024-08-14 | 4 | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Holdings only — no transactions reported | EDGAR |
| 2024-06-11 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Memory SPV II, LP, BIOS Equity Partners III, LP, BIOS Fund III, LP, BIOS Fund III QP, LP, BIOS Fund III NT, LP, BP Directors, LP | Grant/award (A): 8,500 @ $0 · Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 930 @ $6.25 · Sale (S): 1,859 @ $6.33 · Sale (S): 6,944 @ $6.25 · Sale (S): 13,888 @ $6.33 · Sale (S): 2,126 @ $6.25 · Sale (S): 4,253 @ $6.33 | EDGAR |
| 2024-02-29 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 4,649 @ $4.40 · Sale (S): 6,909 @ $4.85 · Sale (S): 1,832 @ $4.87 · Sale (S): 34,731 @ $4.40 · Sale (S): 51,608 @ $4.85 · Sale (S): 13,686 @ $4.87 · +3 more | EDGAR |
| 2024-01-19 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II, LP, BIOS Fund II QP, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Option exercise/expiry (X): 7,347 @ $3.13 · Sale (S): 5,475 @ $4.20 · Option exercise/expiry (X): 54,873 @ $3.13 · Sale (S): 40,893 @ $4.20 · Option exercise/expiry (X): 16,801 @ $3.13 · Sale (S): 12,521 @ $4.20 · +3 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1728851 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →